MAVS expression was evaluated in liver biopsies from people with MASLD (nonalcoholic fatty liver disease activity score [NAS] ≥3) or mild-MASLD livers (NAS ≤2) (Supplemental Table S2, http://links.lww.com/HEP/I457). Here, MAVS is linked to metabolic dysfunction-associated steatotic liver disease.